Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

MK-8141

Known as: ACT-077825 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2014
2014
Background/Aims: The study objective was to investigate and compare the pharmacokinetics of a single oral dose of ACT-077825, a… Expand
  • figure 2
  • table 1
  • table 2
  • figure 3
  • table 3
Is this relevant?
2013
2013
This study was conducted to characterize the multiple-dose tolerability, pharmacokinetics, and pharmacodynamics of ACT-077825, a… Expand
Is this relevant?
2013
2013
This open-label, randomized study evaluated the effects of steady-state diltiazem on the pharmacokinetic, safety, and… Expand
Is this relevant?
2012
2012
PurposeTo evaluate the pharmacokinetics, pharmacodynamics, safety, and tolerability of escalating single oral doses of ACT-077825… Expand
  • figure 1
  • table 1
  • figure 2
  • table 2
  • table 3
Is this relevant?
2010
2010
The renin inhibitor MK-8141 (ACT-077825) demonstrates substantial immunoreactive active renin (ir-AR) increase (sevenfold… Expand
Is this relevant?
2009
2009
(+)-Dapoxetine hydrochloride; Abatacept, Adalimumab, Agalsidase beta, Alemtuzumab, Alglucosidase alfa, Aliskiren fumarate… Expand
Is this relevant?